Off-Label Use of Non-Vitamin K Antagonist Oral Anticoagulants

Off-Label Use of Non-Vitamin K Antagonist Oral Anticoagulants

In their report, Steinberg et al. (1) nicely demonstrate that despite the advantage of uniform non-vitamin K antagonist oral anticoagulants (NOAC) dosing, off-label treatment occurs in approximately 13% of patients, which is related to adverse outcomes.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American College of Cardiology 2017-05, Vol.69 (20), p.2577-2578
Hauptverfasser: van Vugt, Stijn P.G., MD, Brouwer, Marc A., MD, PhD, Verheugt, Freek W.A., MD, PhD
Format: Artikel
Sprache:eng
Schlagworte:
Anticoagulants
Atrial Fibrillation
Cardiac arrhythmia
Cardiology
Cardiovascular
Drug dosages
Drug therapy
Humans
Internal Medicine
Off-Label Use
Registries
Side effects
Vitamin K
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In their report, Steinberg et al. (1) nicely demonstrate that despite the advantage of uniform non-vitamin K antagonist oral anticoagulants (NOAC) dosing, off-label treatment occurs in approximately 13% of patients, which is related to adverse outcomes.
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2017.01.073